PDS Biotechnology (PDSB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.13, -13.08% vs the prior close of $1.30.
- Volume 6.84M shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PDSB slides 13.1% to $1.13, 3 down days in a row. Closed at $1.13, -13.08% vs the prior close of $1.30. Day range $1.09–$1.26, opened at $1.25.
PDSB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PDSB slides 13.1% to $1.13, 3 down days in a row
- Closed at $1.13, -13.08% vs the prior close of $1.30. Day range $1.09–$1.26, opened at $1.25.
- Volume was 6.84M shares, 0.2x its 50-day average of 31.02M — lighter than usual.
- Price is +81.8% vs its 50-day average ($0.62) and +38.7% vs its 200-day average ($0.81).
- 52-week range $0.19–$1.79; today's close sits at 59% of that range, 36.9% below the 52-week high.
- That makes 3 straight losses.
Oct 15, 2026 — PDSB slides 7.8% to $1.30
- Closed at $1.30, -7.80% vs the prior close of $1.41. Day range $1.10–$1.39, opened at $1.37.
- Volume was 10.20M shares, 0.3x its 50-day average of 30.82M — lighter than usual.
- Price is +111.8% vs its 50-day average ($0.61) and +59.9% vs its 200-day average ($0.81).
- 52-week range $0.19–$1.79; today's close sits at 69% of that range, 27.4% below the 52-week high.
Oct 14, 2026 — PDSB slides 11.9% to $1.41
- Closed at $1.41, -11.88% vs the prior close of $1.60. Day range $1.38–$1.67, opened at $1.60.
- Volume was 9.46M shares, 0.3x its 50-day average of 30.64M — lighter than usual.
- Price is +134.1% vs its 50-day average ($0.60) and +73.9% vs its 200-day average ($0.81).
- 52-week range $0.19–$1.79; today's close sits at 76% of that range, 21.2% below the 52-week high.
- SEC filings that day: S-3.
Oct 13, 2026 — PDSB jumps 5.3% to $1.60, a 52-week high, 3 up days in a row
- Closed at $1.60, +5.26% vs the prior close of $1.52. Day range $1.39–$1.79, opened at $1.43.
- Volume was 16.97M shares, 0.6x its 50-day average of 30.31M — lighter than usual.
- Price is +171.9% vs its 50-day average ($0.59) and +98.0% vs its 200-day average ($0.81).
- 52-week range $0.19–$1.79; today's close sits at 88% of that range, 10.6% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — PDSB jumps 10.1% to $1.52, a 52-week high
- Closed at $1.52, +10.14% vs the prior close of $1.38. Day range $1.38–$1.55, opened at $1.49.
- Volume was 15.08M shares, 0.5x its 50-day average of 30.01M — lighter than usual.
- Price is +166.3% vs its 50-day average ($0.57) and +88.9% vs its 200-day average ($0.80).
- 52-week range $0.19–$1.55; today's close sits at 98% of that range, 1.9% below the 52-week high.
Oct 9, 2026 — PDSB jumps 35.3% to $1.38, a 3-month high
- Closed at $1.38, +35.29% vs the prior close of $1.02. Day range $1.00–$1.40, opened at $1.04.
- Volume was 16.06M shares, 0.5x its 50-day average of 29.69M — lighter than usual.
- Price is +149.0% vs its 50-day average ($0.55) and +72.2% vs its 200-day average ($0.80).
- 52-week range $0.19–$1.55; today's close sits at 87% of that range, 11.0% below the 52-week high.
Oct 8, 2026 — PDSB slides 4.2% to $1.02
- Closed at $1.02, -4.23% vs the prior close of $1.07. Day range $0.96–$1.10, opened at $1.04.
- Volume was 4.88M shares, 0.2x its 50-day average of 29.59M — lighter than usual.
- Price is +88.7% vs its 50-day average ($0.54) and +27.7% vs its 200-day average ($0.80).
- 52-week range $0.19–$1.55; today's close sits at 61% of that range, 34.2% below the 52-week high.
Oct 7, 2026 — PDSB rises 1.9% to $1.07
- Closed at $1.07, +1.91% vs the prior close of $1.04. Day range $1.00–$1.10, opened at $1.05.
- Volume was 5.60M shares, 0.2x its 50-day average of 29.48M — lighter than usual.
- Price is +99.6% vs its 50-day average ($0.53) and +33.4% vs its 200-day average ($0.80).
- 52-week range $0.19–$1.55; today's close sits at 64% of that range, 31.3% below the 52-week high.
Oct 6, 2026 — PDSB slides 12.9% to $1.04
- Closed at $1.04, -12.92% vs the prior close of $1.20. Day range $0.94–$1.27, opened at $1.15.
- Volume was 17.04M shares, 0.6x its 50-day average of 29.15M — lighter than usual.
- Price is +98.7% vs its 50-day average ($0.53) and +31.1% vs its 200-day average ($0.80).
- 52-week range $0.19–$1.55; today's close sits at 63% of that range, 32.6% below the 52-week high.
- SEC filings that day: 8-K.
Oct 5, 2026 — PDSB jumps 60.2% to $1.20, a 3-month high on 2.8x normal volume
- Closed at $1.20, +60.21% vs the prior close of $0.75. Day range $0.77–$1.35, opened at $0.78.
- Volume was 78.55M shares, 2.8x its 50-day average of 27.58M — unusually heavy trading.
- Price is +131.2% vs its 50-day average ($0.52) and +50.7% vs its 200-day average ($0.80).
- 52-week range $0.19–$1.55; today's close sits at 74% of that range, 22.6% below the 52-week high.
Oct 2, 2026 — PDSB jumps 6.1% to $0.75
- Closed at $0.75, +6.09% vs the prior close of $0.71. Day range $0.71–$0.75, opened at $0.71.
- Volume was 3.66M shares, 0.1x its 50-day average of 27.51M — lighter than usual.
- Price is +47.3% vs its 50-day average ($0.51) and -5.8% vs its 200-day average ($0.79).
- 52-week range $0.19–$1.55; today's close sits at 41% of that range, 51.7% below the 52-week high.
PDSB latest news & SEC filings
Every SEC filing by or about PDSB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 21, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 21, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$9.75M (prior year -$9.43M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.18 (prior year -$0.21) (loss narrowed vs Jun 30, 2025)
Things to know before you trade PDSB
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 30, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 10.40% (largest 60.2%). That is a volatile stock.
- Liquidity: about 13.05M shares (≈$14.75M) trade per day on average.
- 52-week position: $1.13 vs a range of $0.19–$1.79 (59% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 6, 2026; 8-K Sep 22, 2026; 8-K Sep 21, 2026.
- Share count: 55.97M shares outstanding (Aug 6, 2026), +20.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PDSB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.25 | 1.26 | 1.09 | 1.13 | 6.84M |
| Oct 15, 2026 | 1.37 | 1.39 | 1.10 | 1.30 | 10.23M |
| Oct 14, 2026 | 1.60 | 1.67 | 1.38 | 1.41 | 9.46M |
| Oct 13, 2026 | 1.43 | 1.79 | 1.39 | 1.60 | 16.97M |
| Oct 12, 2026 | 1.49 | 1.55 | 1.38 | 1.52 | 15.08M |
| Oct 9, 2026 | 1.04 | 1.40 | 1.00 | 1.38 | 16.06M |
| Oct 8, 2026 | 1.04 | 1.10 | 0.96 | 1.02 | 4.88M |
| Oct 7, 2026 | 1.05 | 1.10 | 1.00 | 1.07 | 5.60M |
| Oct 6, 2026 | 1.15 | 1.27 | 0.94 | 1.04 | 17.04M |
| Oct 5, 2026 | 0.78 | 1.35 | 0.77 | 1.20 | 78.55M |
| Oct 2, 2026 | 0.71 | 0.75 | 0.71 | 0.75 | 3.66M |
| Oct 1, 2026 | 0.75 | 0.76 | 0.70 | 0.71 | 3.73M |
| Sep 30, 2026 | 0.72 | 0.76 | 0.71 | 0.75 | 4.59M |
| Sep 29, 2026 | 0.75 | 0.77 | 0.73 | 0.74 | 2.71M |
| Sep 28, 2026 | 0.78 | 0.79 | 0.73 | 0.77 | 4.04M |
| Sep 25, 2026 | 0.80 | 0.82 | 0.78 | 0.80 | 3.94M |
| Sep 24, 2026 | 0.81 | 0.81 | 0.75 | 0.80 | 6.10M |
| Sep 23, 2026 | 0.88 | 0.91 | 0.82 | 0.82 | 9.72M |
| Sep 22, 2026 | 0.86 | 1.00 | 0.81 | 0.91 | 24.75M |
| Sep 21, 2026 | 0.94 | 0.97 | 0.81 | 0.84 | 17.07M |
About PDS Biotechnology
PDS Biotechnology (PDSB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1472091.
PDSB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kamil Ali-Jackson | Director | Mar 3, 2026 |
| Frank Bedu-Addo | President/CEO | Mar 3, 2026 |
| Otis W Brawley | Director | Mar 3, 2026 |
| Arnold James Banaag | Director | Sep 21, 2026 |
| Gregory Gene Freitag | Director | Mar 3, 2026 |
| Stephen C. Glover | Director | Mar 3, 2026 |
| Ilian Iliev | Director | Mar 3, 2026 |
| Patrick Soon-Shiong | Director | Sep 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Frank Bedu-Addo | President/CEO | Mar 3, 2026 |
| Lars Boesgaard | Chief Financial Officer | Mar 3, 2026 |
| Spencer D. Brown | Senior VP, General Counsel | Mar 3, 2026 |
| Gregory Conn | Chief Scientific Officer | Mar 3, 2026 |
| Kirk V. Shepard | Chief Medical Officer | Mar 3, 2026 |
| Stephan Toutain | Chief Operating Officer | Mar 3, 2026 |
| Janetta Trochimiuk | Principal Accounting Officer | Sep 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
PDSB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-34.50M | -0.74 | $-27.75M |
| Dec 31, 2024 | — | $-37.61M | -1.03 | $-35.03M |
| Dec 31, 2023 | — | $-42.94M | -1.39 | $-33.64M |
| Dec 31, 2022 | — | $-40.85M | -1.43 | $-25.71M |
| Dec 31, 2021 | — | $-16.92M | -0.66 | $-12.49M |
Latest balance sheet: total assets $8.81M, total liabilities $12.39M, cash $5.60M (as of Jun 30, 2026).
PDSB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $0.23 |
| May 13, 2026 | 8-K Item 2.02 (results) | $1.33 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $0.54 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $0.85 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $0.96 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $1.16 |
| May 14, 2025 | 8-K Item 2.02 (results) | $1.31 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $1.25 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $2.25 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PDSB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.